Trial Profile
An Open Label Study for the Evaluation of Tolerability of Five Dose Levels of Cand5 by Single Intravitreal Injection in Patients With Wet Age-Related Macular Degeneration
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Oct 2014
Price :
$35
*
At a glance
- Drugs Bevasiranib (Primary)
- Indications Wet age-related macular degeneration
- Focus Adverse reactions
- Sponsors OPKO Health
- 09 Oct 2014 New trial record